JC14 Rec'd PCT/PTO 26 APR 2005

عانا به الحال			9 9 1 8 8 8	, 5003
·				Page 1 of 1
Attorney Docket:	A No.:	10	1522	700

FORM PTO-1449B

INFORMATION DISCLOSURE CITATION

4439-4032	Not Yet Assigned 939100
Applicant:	
Toshiyuki TAKAI et al.	
Filing Date:	Group Art Unit:
April 26, 2005	Not Yet Assigned

		11p111 20, 2003 1101 1001g110		
		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		YUASA T. et al., Deletion of fc gamma receptor IIB renders H-2(b) mice susceptible to		
AS	1.	collagen-induced arthritis, J. Exp. Med. (1999), Vol. 189, No. 1, p.187-94.		
AS	2.	TAKAI T. et al., Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice, Nature (1996), Vol. 379, No. 6563, p. 346-49.		
AS	3.	ODAKA M. et al., N-glycolylneuraminic acid-containing GM1 is a new molecule for serum antibody in Guillain-Barre syndrome, Ann. Neurol. (1998), Vol. 43, No. 6, p.829-34.		
Not dong i don KEIICHIRO SUSUKI et al., Jikusakugata Guillain-Barre Shokogun Model Dobutsu no				
	1011014 <u>e</u>	Juritsu: 2" report, Men'ekisei Shinkei Shikkan ni Kansuru Chosa Kenkyuhan Heisei 12 Nendo Kenyu Hokokusho (2001) p 111-12 No English Trap		
	4.	Nendo Kenyu Hokokusho (2001), p.111-12.	18	
	5.	·		
	6.	·		
	7.			
	8.			
	9.			
	10.			
	11.			
	12.			
	13.			
	14.			
	15.	·		
	16.			
	17.			
	18.			

Examiner	/Anoop Singh/	Date	10/31/2006
Signature		Considered	10/31/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.